The effectiveness of treatment refractory neyroblastoma in children

Summary. The aim of this work was to determine the effec­tiveness of the regime topotekan, doxorubicin and vinkrystyn in children with refractory forms of neuroblastoma. In the group of children who received treatment topotekan, doxorubicin and vinkrystyn number of boys was 14, girls — 7. All patients were older than 1 year, most are children 2–5 years, with refractory forms of neuroblastoma that were treated at the National Institute for Cancer Pediatric Oncology from 2004 to 2008. To achieve remission in patients with refractory forms of neuroblastoma main group therapy as the second line was developed regime topotekan, doxorubicin and vinkrystyn. The essence of the proposed regime was to use a combination drug with topoisomerase inhibitors group – topotekanu, not previously used in the treatment of this pathology, the traditional medicines that have proved effective in the treatment of neuroblastoma – doxorubicin and vinkrystyn. Positive response to treatment in the proposed scheme was observed in 16 of 21 patients (84,2%) (complete remission — 42,1%, the stabilization process — 42,1%), 5 – confirmed disease progression. The scheme of chemotherapy by topotekan in combination with doxorubicin and vinkrystynom found highly effective in treating children with refractory forms of neuroblastoma. Complete remission and stabilization process achieved in 84,2%. Overall 3-year survival is 38%.